Phase 1/2a, Multicenter, Randomized, Dose Escalation, Fellow-Eye Controlled, Study Evaluating the Safety and Clinical Response of a Single, Subretinal Administration of Human Umbilical Tissue-Derived Cells (CNTO 2476) in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy Secondary to Age-related Macular Degeneration

Trial Profile

Phase 1/2a, Multicenter, Randomized, Dose Escalation, Fellow-Eye Controlled, Study Evaluating the Safety and Clinical Response of a Single, Subretinal Administration of Human Umbilical Tissue-Derived Cells (CNTO 2476) in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy Secondary to Age-related Macular Degeneration

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs CNTO 2476 (Primary)
  • Indications Dry macular degeneration
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 01 Jul 2017 Results published in the American Journal of Ophthalmology
    • 01 Jul 2017 Status changed from active, no longer recruiting to completed, as per results published in the American Journal of Ophthalmology.
    • 12 May 2017 Planned End Date changed from 1 Nov 2019 to 30 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top